FINANCINGS

Anaptysbio Inc. set terms for its IPO of 4 million common shares priced in a range of $14 to $16 apiece, seeking to raise net proceeds of approximately $51.8 million.

Braeburn Pharmaceuticals Inc. set terms for its proposed IPO and will seek to raise $150 million by offering approximately 7.7 million shares priced between $18 and $21.

Cristal Therapeutics BV secured $13.7 million in a new financing round.

Emergent Biosolutions Inc. paid its newly launched oncology and hematology-focused spin-off, Aptevo Therapeutics Inc., $20 million, raising its contributions to fund its operations to $65 million.

Jounce Therapeutics Inc. set terms for its IPO, seeking to raise $75 million by offering 5.36 million common shares priced in a range of $13 to $15.

Phasebio Pharmaceuticals Inc. closed a financing of $14.7 million in convertible notes.

Zynerba Pharmaceuticals Inc. priced a public offering of 2.8 million shares of common stock at $18 per share for gross proceeds of $50.4 million.

DEALS

Eli Lilly and Co. is acquiring Colucid Pharmaceuticals Inc. for about $960 million.

Cancer Genetics Inc. has established a strategic collaboration with Lantern Pharma Inc. on biomarker discovery, clinical trials and genomics projects for Lantern's lead clinical candidates.

Cancer Research UK, Cancer Research Technology and MRC Technology report that they are collaborating to identify and validate drug discovery targets that could lead to new immunotherapy treatments.

Cytori Therapeutics Inc. is acquiring two nanoparticle cancer candidates developed by Azaya Therapeutics Inc.

Evotec AG and MaRS Innovation launched Fibrocor Therapeutics LP to develop therapies targeting the prevention, slowing and reversal of fibrotic diseases.

Evotec AG inked an integrated drug discovery collaboration on an undisclosed ion channel target with Asahi Kasei Pharma Corp., a unit of Asahi Kasei Corp.

Leon-Nanodrugs GmbH and Bionpharma Inc. said they inked a cooperative agreement to develop a dermatology product via Leon's Microjet Reactor, a nanotechnology platform.

Les Laboratoires Servier SAS and Masthercell SA signed a master service agreement for the development of a manufacturing platform for allogeneic cell therapies.

Malin Corp. plc has acquired a 33 percent shareholding of Wren Therapeutics Ltd., a newly created biopharmaceutical company with a focus on drug discovery and subsequent clinical translation of molecules aimed at affecting protein misfolding diseases.

Novan Inc. signed a license agreement with Sato Pharmaceutical Co. Ltd. for SB204 to treat acne vulgaris.

Pharmathene Inc. and Altimmune Inc. have agreed to merge in an all-stock transaction that the companies said will create a fully integrated and diversified immunotherapeutics company with one preclinical and four clinical-stage programs.

Regeneus Ltd. formed a strategic collaboration and licensing agreement with AGC Asahi Glass Co. for the manufacture, clinical development and commercialization of Progenza, a patented, off-the-shelf stem cell technology platform, for the Japanese market.

. . . AND MORE

Alcobra Ltd. is halting development of metadoxine extended release in the lead indication of attention deficit hyperactivity disorder in adults after the phase III registration trial, MEASURE, failed to demonstrate a statistically significant difference from placebo.

At the World Economic Forum 22 biopharma companies launched Access Accelerated, a global effort to advance access to non-communicable disease prevention and care in low and lower-middle income countries.

Biomotiv, a drug development accelerator, and the University of Auckland, New Zealand, have formed Sapvax, which will develop cancer vaccines.

Corbus Pharmaceuticals Holdings Inc. said the European Commission granted orphan designation for its synthetic oral endocannabinoid-mimetic drug, JBT-101, to treat systemic sclerosis.

Forward Pharma A/S is receiving a $1.25 billion cash payment from Biogen Inc. in a partial settlement of their intellectual property dispute over the use of dimethyl fumarate for treating multiple sclerosis.

Lysogene SAS said the FDA granted rare pediatric disease designation to LYS-GM101, its drug candidate in development for patients with GM1 gangliosidosis, a severe neurodegenerative disease.

Nivalis Therapeutics Inc. will lay off 25 employees as part of a restructuring plan that seeks to preserve its cash while it assesses its options in the wake of the phase II failure of its lead candidate, cavosonstat (N91115), to benefit certain adult patients with cystic fibrosis.

Teva Pharmaceutical Industries Ltd. gained FDA approval for Vantrela ER (hydrocodone bitartrate) extended-release tablets formulated with the company's abuse-deterrence technology.

Xcovery Inc. is participating in the NCI Formulary, a public-private partnership between the National Cancer Institute and the biopharma industry to expedite the use of agents in clinical trials.